Methods We did a randomised, double-blind, parallel-group, phase 3, non-inferiority trial in 76 centres in 17 countries in Asia, Europe, and the USA (APEKS-NP). We enrolled adults aged 18 years and older with hospital-acquired, ventilator-associated, or health-care-associated Gram-negative...
问题描述:甲状腺指标一项过高,想给看看报告(女,54岁) 病情分析:可能疾病:甲状腺乳头状癌术后 意见详情:建议将优甲乐的剂量减半,定期监测甲状腺功能指标,特别是甲状腺过氧化物酶抗体水平。由于患者有甲状腺癌病史,需密切关注甲状腺功能变化。保持规律的生活作息,避免过度疲劳,均衡饮食,适量摄入碘和硒等营养素,定期复查甲状...
Clinicaltrials.gov: APEKS-NP: NCT03032380; CREDIBLE-CR: NCT02714595.Patrice NordmannRyan K. ShieldsYohei DoiMiki TakemuraRoger EcholsYuko MatsunagaYoshinori YamanoMicrobial Drug Tesistance:Mechanisms,Epidemiology and Disease(631B0162)
This antibiotic performed well in the APEKS-NP trial for the treatment of nosocomial pneumonia caused largely by carbapenem susceptible isolates. However, in the CREDIBLE-CR trial involving exclusively CR Gram-negative bacteria, cefiderocol was associated with a higher rate of all-cause mortality. ...
Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?doi:10.1016/S2666-5247(21)00271-8Jacob E.ChobyEmory Antibiotic Resistance Center, Atlanta, GA 30329, USA; Emory Vaccine Center, Atlanta, GA, USA.Tugba.Ozturk...